SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Cigna Corporation (CI) trades at a trailing P/E of 12.4, forward P/E of 9.0. Trailing earnings yield is 8.07%, forward earnings yield 11.12%. PEG 0.15 (Peter Lynch undervalued ≤1.0). Graham Number is $281.70.
Criteria proven by this page:
- VALUE (80/100, Pass) — P/E is below market average (12.4); PEG ≤ 1.0 — Peter Lynch undervalued (0.15); analyst target implies upside (+19.5%); earnings yield beats bond yields (8.07%).
- Forward P/E 9.0 (down from trailing 12.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.15 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 8.07% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 11.12% as earnings recover.
- Analyst consensus target $325.83 (+19.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 62/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
80/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CI
Valuation Multiples
P/E (TTM)12.4
Forward P/E9.0
PEG Ratio0.15
Forward PEG0.24
P/B Ratio1.77
P/S Ratio0.27
EV/EBITDA8.2
Per Share Data
EPS (TTM)$22.40
Forward EPS (Est.)$30.31
Book Value / Share$157.45
Revenue / Share$1,033.86
FCF / Share$31.54
Yields & Fair Value
Earnings Yield8.07%
Forward Earnings Yield11.12%
Dividend Yield2.19%
Graham Number$281.70
SharesGrow IV$810.27 (+197.2%)
Analyst Target$325.83 (+19.5%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
18.2 |
-1.73 |
2.48 |
0.86 |
0.03% |
| 2017 |
22.1 |
0.87 |
3.61 |
1.19 |
0.02% |
| 2018 |
17.8 |
1.07 |
1.14 |
0.96 |
0.02% |
| 2019 |
15.1 |
0.56 |
1.70 |
0.50 |
0.02% |
| 2020 |
9.0 |
0.13 |
1.51 |
0.47 |
0.02% |
| 2021 |
14.5 |
-0.46 |
1.65 |
0.45 |
1.73% |
| 2022 |
15.5 |
0.43 |
2.31 |
0.57 |
1.33% |
| 2023 |
17.2 |
-0.91 |
1.92 |
0.46 |
1.63% |
| 2024 |
22.5 |
-0.74 |
1.89 |
0.31 |
2.02% |
| 2025 |
12.3 |
0.15 |
1.75 |
0.27 |
2.20% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$7.19 |
$40.01B |
$1.87B |
4.7% |
| 2017 |
$9.17 |
$42.04B |
$2.24B |
5.3% |
| 2018 |
$10.54 |
$48.57B |
$2.64B |
5.4% |
| 2019 |
$13.44 |
$153.74B |
$5.1B |
3.3% |
| 2020 |
$22.96 |
$160.55B |
$8.46B |
5.3% |
| 2021 |
$15.75 |
$174.27B |
$5.37B |
3.1% |
| 2022 |
$21.30 |
$180.03B |
$6.7B |
3.7% |
| 2023 |
$17.39 |
$195.19B |
$5.16B |
2.6% |
| 2024 |
$12.12 |
$244.38B |
$3.43B |
1.4% |
| 2025 |
$22.17 |
$274.95B |
$5.96B |
2.2% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$30.32 |
$30.07 – $30.49 |
$284.86B |
$280.74B – $292.82B |
15 |
| 2027 |
$33.43 |
$32.88 – $34.43 |
$301.79B |
$278.53B – $317.63B |
14 |
| 2028 |
$37.09 |
$31.57 – $40.96 |
$319.81B |
$317.63B – $321.99B |
8 |
| 2029 |
$41.01 |
$39.28 – $43.25 |
$352.72B |
$341.26B – $367.53B |
6 |
| 2030 |
$45.90 |
$43.96 – $48.41 |
$389.85B |
$377.18B – $406.21B |
6 |
